Late effects of cancer are common, and they may appear immediately after treatment or years after treatment. The effects differ from one cancer survivor to another. They can be mild or severe, some of which improve or fade with time while others may be permanent. Late effects depend on the type of medication a patient uses.
Scientists have developed the antibody-drug conjugates that are designed to specifically kill cancer cells and spare non-targeted cells to eliminate the late effects of traditional cancer treatments. The technology minimizes the harmful effects of traditional chemotherapy and has the possibility of improving antitumor activity. The antibody-drug conjugates (ADCs) are engineered to control the capability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Designed monoclonal antibodies have provided therapeutic benefit to cancer patients as well as those with acute medical conditions.
Seattle Genetics is a biotechnology company that has pioneered the development of antibody drug conjugates (ADCs) for the treatment of cancer. The company’s first product in its new class of ADCs is the ADCETRIS® (brentuximab vedotin) which received an accelerated FDA approval in 2011. ADCETRIS is currently available in 65 countries including the United States, Japan, Canada and members of the European Union.
The biotechnology company is carrying out continuous research activities to advance its technology. Seattle Genetics has over 20 ADCs in clinical development that use proprietary technology such as co-development programs and multiple collaborator programs. Apart from ADCETRIS, the company has an internal pipeline of auristatin-based ADCs that include SGN-LIV1A and SGN-CD19A as well as ASG-22ME and ASG-15ME.
In 1998, Clay Siegall and H. Perry Fell founded Seattle Genetics. Dr. Clay Siegall serves as the CEO, president and chairperson of the board for Seattle Genetics. He co-founded the company with the objective of developing cancer treatment therapies through rigorous research and scientific innovation. Through Clay Siegall, the company has developed a wide portfolio of clinical and preclinical products targeting various types of cancer and autoimmune diseases.
Dr. Siegall is a scientist by training and has more than 20 years of experience in therapeutic drug development and cancer research. He studied Zoology at the University of Maryland and Genetics in George Washington University where he attained his Ph.D.